Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial
Isa et al., The Lancet Infectious Diseases, doi:10.1016/S1473-3099(24)00421-3
https://c19early.org/isa2.html